



Centre for AIDS Reagents

Data Sheet

NAME:	Pseudotyped virus SIVmac239CS.23(pSG3?env)/293T/17
REPOSITORY REFERENCE:	ARP1156 (200908055141P)
HARVEST DATE:	07/AUG/09
DESCRIPTION:	SIV gp160 clone for use as Env-pseudotyped virus
HOST CELLS:	293T/17 (P36)
ENVELOPE SPECIFICATION:	SIVmac239CS.23
BACKBONE PLASMID:	pSG3 delta env (was derived from pSG3.1 by partial SpeI digestion, Klenow filling of the 3' recessed ends and religation. This introduced a four nucleotide insertion mutation (CTAG) in env and a translation stop codon after amino acid residue 142). Accession number: L02317
RECOMMENDED VIRUS DILUTION IN NEUTRALISING ANTIBODY IN TZM-BL CELLS:	1:15 1:10 (1x thawed)
PROJECTED RLU EQUIVALENCE	182.000

PRESENTATION:

IN TZM-BL CELLS:

1 ml

National Institute for Biological Standards and Control – Assuring the quality of biological medicines Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG United Kingdom Tel +44 (0)1707 641000 Fax +44 (0)1707 641050 www.nibsc.ac.uk A World Health Organization Laboratory for Biological Standards







STORAGE:	-80°C
BIOHAZARD:	Biosafety Level II or III as HIV-1 Env-pseudoviruses are revertible to replication competent HIV
SOURCE:	Env plasmid was provided by David Montefiori and the backbone plasmid was contributed by John Kappes and Xiaoyun Wu.
	SIV pseudotyped virus was produced by Stefanie Koch, Andreas Meyerhans and Hagen von Briesen at HSC (HIV Specimen Cryorepository) under GCLP conditions.
REFERENCES:	Wei S, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, and Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905, 2002.
	Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzales JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD and Shaw GM. Antibody neutralization and escape by HIV-1. Nature 422: 307-312, 2003.
LEGAL NOTE:	Consultation needed
	The HIV pseudovirus production and distribution project is a collaborative effort of the Comprehensive Antibody Vaccine Immune Monitoring Center (CA-VIMC) (PI David Montefiori) and the HIV Specimen Cryorepository (HSC) (PI Hagen von Briesen) within the Collaboration for AIDS Vaccine Discovery (CAVD) (founded by the Bill and Melinda Gates foundation).
	Production, quality control and distribution of HIV-1 Env- pseudoviruses is conducted by the HSC (Stefanie Koch, Hagen von Briesen). HIV Env-pseudoviruses are provided on a collaborative basis with Stefanie Koch, Andreas Meyerhans and Hagen von Briesen

.



Briesen.





ACKNOWLEDGEMENTS:

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website in the "Acknowledgements" section at:

www.nibsc.ac.uk/spotlight/centre for aids reagents.aspx

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)

